沙库巴曲缬沙坦在全射血分数范围心衰中疗效的假定安慰剂分析
本研究基于PARADIGM-HF、PARAGON-HF、CHARM-Alternative和CHARM-Preserved试验的患者水平数据,通过间接比较估计沙库巴曲缬沙坦 vs 假定安慰剂对心衰患者心血管事件的影响。结果示沙库巴曲缬沙坦显著降低复发主要终点(RR 0.54,95%CI 0.45-0.65),获益随LVEF呈非线性变化,LVEF>60%时减弱。
要点
- 沙库巴曲缬沙坦 vs 假定安慰剂降低复发主要终点RR 0.54(95%CI 0.45-0.65,P<0.001)。
- LVEF≥45%人群风险降低29%(95%CI 7-46%,P=0.013),LVEF降低人群降低48%(95%CI 35-58%)。
- 获益在LVEF>60%时减弱,提示高LVEF患者疗效可能有限。
核心结论
- 假定安慰剂分析支持沙库巴曲缬沙坦在全LVEF范围降低心血管事件风险,LVEF≤60%时获益最明显。
研究设计与样本
- 分析PARADIGM-HF和PARAGON-HF(n=13 194)及CHARM-Alternative和CHARM-Preserved(n=5 050,坎地沙坦 vs 安慰剂)的患者水平数据。
- 通过沙库巴曲缬沙坦 vs RASi的RR与RASi vs 安慰剂的RR相乘估计沙库巴曲缬沙坦 vs 假定安慰剂的RR。
- 采用负二项方法分析总心衰住院和心血管死亡,用立方样条法以LVEF为连续变量估计疗效。
主要发现
- 全LVEF范围,沙库巴曲缬沙坦 vs 假定安慰剂复发主要终点RR 0.54(95%CI 0.45-0.65,P<0.001)。
- PARADIGM-HF与CHARM-Alternative分析中,估计风险降低48%(95%CI 35-58%,P<0.001)。
- PARAGON-HF与CHARM-Preserved(LVEF≥45%)分析中,估计风险降低29%(95%CI 7-46%,P=0.013)。
- 全LVEF范围,首次主要终点RR 0.72(95%CI 0.64-0.82),首次心衰住院RR 0.67(95%CI 0.58-0.78),心血管死亡RR 0.76(95%CI 0.64-0.89),全因死亡RR 0.83(95%CI 0.71-0.96),均P<0.02。
- 沙库巴曲缬沙坦 vs 假定安慰剂的治疗获益随LVEF呈非线性变化,LVEF>60%时减弱。
临床怎么用
- 对于LVEF≤60%的心衰患者,沙库巴曲缬沙坦可考虑用于降低心血管事件风险。
- LVEF>60%的患者获益减弱,临床决策需个体化权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan against active controls given renin-angiotensin system inhibitors (RASi) are ethically mandated in heart failure (HF) with reduced ejection fraction and are used in the vast majority of patients with HF with preserved ejection fraction. To estimate the effects of sacubitril/valsartan had it been tested against a placebo control, we made indirect comparisons of the effects of sacubitril/valsartan with putative placebos in HF across the full range of left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We analysed patient-level data from the PARADIGM-HF and PARAGON-HF trials (n = 13 194) and the CHARM-Alternative and CHARM-Preserved trials (n = 5050, candesartan vs. placebo). The rate ratio (RR) of sacubitril/valsartan vs. putative placebo was estimated by the product of the RR for sacubitril/valsartan vs. RASi and the RR for RASi vs. placebo. Total HF hospitalizations and cardiovascular death were analysed using the negative binomial method. Treatment effects were estimated using cubic spline methods by ejection fraction as a continuous measure. Across the range of LVEF, sacubitril/valsartan was associated with a RR 0.54 [95% confidence interval (CI) 0.45-0.65] for the recurrent primary endpoint compared with putative placebo (P < 0.001). Treatment benefits of sacubitril/valsartan vs. putative placebo varied non-linearly with LVEF with attenuation of effects observed at LVEF above 60%. When analyzing data from PARADIGM-HF and CHARM-Alternative, the estimated risk reduction of sacubitril/valsartan vs. putative placebo was 48% (95% CI 35-58%); P < 0.001. When analyzing data from PARAGON-HF and CHARM-Preserved (with LVEF ≥ 45%), the estimated risk reduction of sacubitril/valsartan vs. putative placebo was 29% (95% CI 7-46%); P = 0.013. Across the full range of LVEF, consistent effects were observed for time-to-first endpoints: first primary endpoint (RR 0.72, 95% CI 0.64-0.82), first HF hospitalization (RR 0.67, 95% CI 0.58-0.78), cardiovascular death (RR 0.76, 95% CI 0.64-0.89), and all-cause death (RR 0.83, 95% CI 0.71-0.96); all P < 0.02. CONCLUSION: This putative placebo analysis reinforces the treatment benefits of sacubitril/valsartan on risk of adverse cardiovascular events across the full range of LVEF, with most pronounced effects observed at a LVEF up to 60%.
引用
- Vaduganathan M, Jhund PS, Claggett BL, et al. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J. 2020. PMID: 32221596. doi:10.1093/eurheartj/ehaa184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。